EGFR Mutations in Head and Neck Cancer Patients Treated with Gefitinib
Author Information
Author(s): Murray Samuel, Bobos Mattheos, Angouridakis Nikolaos, Nikolaou Angelos, Linardou Helena, Razis Evangelia, Fountzilas George
Primary Institution: GeneKOR S.A.
Hypothesis
If somatic mutations and gene copy gain of EGFR occur in H and N cancer, then treatment with a TKI such as gefitinib could be a potentially beneficial treatment option for many of these patients.
Conclusion
The incidence of EGFR mutations in head and neck cancer was found to be low, and no significant correlations between mutation status and treatment response or survival were observed.
Supporting Evidence
- Mutations were detected in 6 out of 19 patients.
- The incidence of EGFR mutations in this study was 5.3%.
- No significant differences in TTP or OS for patients with somatic EGFR mutations were observed.
- Patients with somatic EGFR mutations had a longer TTP and survival compared to those without mutations, but it was not statistically significant.
Takeaway
This study looked at patients with head and neck cancer to see if a specific drug, gefitinib, could help them based on their genes. They found that only a few patients had the right gene changes, and it didn't really help them live longer.
Methodology
Patients with histologically confirmed head and neck cancer who failed prior treatment were treated with gefitinib, and their EGFR mutation status was analyzed.
Potential Biases
Potential selection bias due to the small number of patients and the specific cohort studied.
Limitations
The small sample size limits the ability to draw definitive conclusions about the predictive value of the biomarkers studied.
Participant Demographics
Predominantly white males, median age 66 years, with a strong smoking history.
Statistical Information
Confidence Interval
95% CI: 1.5–5.6 for TTP; 95% CI: 2.4–10.6 for survival.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website